Tick-borne flaviviruses (TBFVs) can cause life-threatening encephalitis and hemorrhagic fever. To identify virus-host interactions that may be exploited as therapeutic targets, we analyzed the TBFV polyprotein in silico for antiviral protein-binding motifs. We obtained two putative tumor necrosis factor receptor-associated factor 6 (TRAF6)-binding motifs (TBMs) within the protease domain of the viral nonstructural 3 (NS3) protein. Here, we show that TBFV NS3 interacted with TRAF6 during infection and that TRAF6 supports TBFV replication. The proviral role of TRAF6 was not seen with mosquitoborne flaviviruses, consistent with the lack of conserved TBMs. Mutation of the second TBM within NS3 disrupted TRAF6 binding, coincident with reduced abundance of mature, autocatalytically derived form of the NS3 protease and significant virus attenuation in vitro. Our studies reveal insights into how flaviviruses exploit innate immunity for the purpose of viral replication and identify a potential target for therapeutic design.
HIGHLIGHTS Langat virus (LGTV) NS3 protease interacts with TRAF6 during infection
Tick-borne, unlike mosquito-borne, flaviviruses use TRAF6 for optimal replication E117A mutation of LGTV NS3 reduces TRAF6 binding and mature protease abundance
LGTV with a mutated TRAF6-binding motif is attenuated in vitro
INTRODUCTION
Viruses within the Flavivirus genus represent an overwhelming disease burden to humans, in worst cases causing either encephalitis or hemorrhagic fever with mortality rates up to 50% (Leyssen et al., 2000) . The success of flaviviruses is in large part associated with transmission by arthropod vectors, either mosquito borne, represented by dengue virus (DENV), West Nile virus (WNV), and Zika virus, or tick borne, including tick-borne encephalitis virus (TBEV), Omsk hemorrhagic fever virus, Kyasanur Forest disease virus (KFDV), and Powassan virus (POWV) . No specific antiviral therapy is available for the millions of individuals infected with flaviviruses each year. We rationalize that to develop desperately needed drugs and vaccines to treat and prevent flavivirus infections, we need to better understand how flaviviruses infect cells and cause disease.
The flavivirus chymotrypsin-like serine protease, nonstructural 3 (NS3), is an ideal target for broad-spectrum antiviral development (Luo et al., 2015) . NS3 is relatively conserved between the flaviviruses and is essential for virus replication, functioning to cleave the viral polyprotein into mature individual proteins through a well-characterized enzymatic function (Li et al., 2014; Palanisamy et al., 2018) . Mutant flaviviruses with an inactive NS3 protease are unable to generate infectious virions (Chambers et al., 2005) . Despite substantial effort and resources directed toward the design of NS3 protease inhibitors, there has only been limited success and no compound has reached the clinical trial stage (Brecher et al., 2017) . Innovative discovery approaches seek to expand potential drug targets by identifying protein-protein interactions necessary for viral protein function during infection (Geiss et al., 2009 ). We reasoned here that the identification of host proteins that interact with NS3 may direct us toward methods to inhibit NS3, either by modeling antiviral drugs from host antiviral interactions with NS3, or by identifying host proteins that NS3 uses during infection.
Bioinformatic analysis of the TBEV polyprotein revealed a potential interaction with the host protein tumor necrosis factor receptor-associated factor 6 (TRAF6). TRAF6 is an important antiviral intracellular molecule for the interleukin-1(IL-1)/Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I) signaling pathways (Inoue et al., 2007; Wu and Arron, 2003; Yoshida et al., 2008) . It functions by linking innate immune receptor engagement to activation of protein kinase complexes, culminating in activation of transcription factors including nuclear factor-kB (NF-kB) and activator protein-1 (Walsh et al., 2015) . TRAF6 is an E3 A B
C D E ubiquitin ligase and binds substrate proteins through a conserved TRAF6 binding motif (TBM) . A canonical TBM is formed from the amino acid sequence P-X-E-X-X-Ac/Ar (X representing any amino acid, Ac/Ar representing either an acidic or aromatic residue) (Chung et al., 2007) . TRAF6 has also been shown to bind to non-canonical TBMs that have alternative amino acids sequences (Gentry et al., 2004; Meads et al., 2010; Noels et al., 2007; Stack et al., 2013) .
In this study, we discovered and experimentally validated a TBM in NS3 of tick-borne flaviviruses (TBFVs), which is not present in mosquito-borne flaviviruses (MBFVs). The protein interaction between TRAF6 and NS3 is disrupted by site-directed mutagenesis, and, in the context of the full TBFV genome, the mutation results in virus attenuation. We found that TBM mutation within NS3 impairs the expression of the mature, active form of the viral protease (NS3pro). NS3pro is only produced during infection by autoproteolytic cleavage and is essential for flavivirus replication. Our data suggest that TRAF6 actively participates in the TBFV replication cycle to maintain NS3pro expression, possibly through protein stabilization or protease activation. Thus TRAF6's structural and functional contributions to NS3pro maturation, in addition to the TRAF6-NS3 complex, serve as potential therapeutic targets that should be further explored for treatment of the TBFVs.
RESULTS

TBFV, but Not MBFV, NS3pro Interacts with TRAF6
To investigate the cellular factors regulating TBFV replication, we performed a bioinformatic analysis of the TBEV polyprotein using the Eukaryotic Linear Motif Resource for Functional Sites in Proteins . Our primary screen revealed a solitary putative canonical TBM, P-F-E-V-K-D (TBM1), located within the protease domain of NS3 (NS3pro) between residues 17 and 22 ( Figure 1A ). Further analysis of NS3pro identified a non-canonical putative TBM,
, at residues 115-120, in which the terminal amino acid of the consensus sequence is neither acidic nor aromatic ( Figure 1A ) (Gentry et al., 2004) . Sequence alignment of NS3pro from other flaviviruses showed that the two putative TBMs are highly conserved among TBFVs (Figures 1A and S1A-S1C), with the exception of the evolutionarily isolated POWV (Hermance and Thangamani, 2017) . TBM2 was not present in NS3 of POWV. Furthermore, we did not identify TBM1 or TBM2 in any MBFV ( Figure 1A ), suggesting a possible unique and specific interaction between TBFVs and TRAF6.
Based on our bioinformatics results, we first examined a potential interaction between TBFV NS3 and TRAF6 using immunofluorescent microscopy. For this purpose, human embryonic kidney (HEK) 293 cells expressing either GFP or a GFP-tagged TRAF6 (TRAF6-GFP) were infected with Langat virus (LGTV), a prototypical member of the TBEV serogroup. Confocal analyses revealed strong co-localization of LGTV NS3 and TRAF6 proteins at 24 h post-infection (hpi) ( Figure 1B) . We also observed a change in the cellular distribution of TRAF6-GFP, from discrete puncta in uninfected cells to a large perinuclear aggregate during infection ( Figure 1B ). To validate the confocal results, we took a biochemical approach and preformed a coimmunoprecipitation (coIP) of endogenous TRAF6 with LGTV NS3. HEK293 cells were infected with LGTV, and at 48 hpi, anti-NS3 antibody was used to precipitate LGTV NS3. We were able to pull down Figure S1 .
iScience 15 endogenous TRAF6 with LGTV NS3 ( Figure 1C ). In addition, we tested the specificity of TBFV NS3 to interact with TRAF6 by preforming a coIP with HEK293 cells expressing TRAF6-GFP. Cells were either infected with LGTV or Kunjin virus (KUNV), an MBFV that lacks TBM1 and TBM2 ( Figure 1A ), and at 48 hpi, anti-GFP antibody was used to precipitate TRAF6-GFP. We were only able to pull down LGTV NS3 with TRAF6-GFP ( Figure 1D ). These results suggest that LGTV NS3 and TRAF6 proteins interact during TBFV infection.
To identify the structural and functional requirements of the LGTV NS3pro-TRAF6 interaction, we engineered epitope-tagged recombinant NS3 constructs and compared their interaction with wild-type (WT) TRAF6 using a co-affinity purification (coAP) technique based on biotin-streptavidin binding . NS3 protease activity is dependent on a non-covalent interaction with NS2B (Erbel et al., 2006; Falgout et al., 1991) . To express NS3 with a functional protease domain, we fused NS2B and NS3 together in a single open reading frame, as occurs in the polyprotein (NS2B/3). Once translated within the cell, the NS2B/3 polyprotein undergoes autocatalytic cleavage, freeing NS2B from NS3 (Bera et al., 2007; Liu et al., 2017) . This cleavage event is detected on immunoblot as a doublet, with NS2B/3 having a larger molecular weight than NS3 alone. As a confirmation of the interaction detected during virus infection, TRAF6 precipitated both full-length LGTV NS2B/3 and truncated LGTV NS2B/3pro when expressed in HEK293 cells ( Figure 1E ). Next, we engineered the following two constructs to directly test the requirement of NS3 protease activity for NS3pro binding to TRAF6: (1) an LGTV NS3pro construct that lacks NS2B and thus has no enzymatic activity and (2) a mutated LGTV NS3 serine 138 to alanine, which disrupts the catalytic triad needed for protease activity (Pastorino et al., 2006) . We found in both instances that NS3 was able to interact with TRAF6 regardless of a functional NS3 protease ( Figures 1E, S1D , and S1E). Finally, LGTV NS5, the major interferon (IFN) antagonist of TBFVs (Best et al., 2005) , was not precipitated with TRAF6 and served as a negative control, whereas TRAF6 forms a strong homomeric complex with alternatively tagged TRAF6 as previously reported (Megas et al., 2011 ) ( Figure 1E ). These results show that TRAF6 specifically interacts with the protease domain of LGTV NS3 and that the protease activity of NS3 is not required for this interaction.
TBFVs Use TRAF6 for Optimal Replication
To assess the role of TRAF6 in TBFV replication, we infected WT and TRAF6 À/À murine embryonic fibroblasts (MEFs) with LGTV. In contrast to what we predicted, we found that TRAF6 is needed for optimal
LGTV replication ( Figures 2A-2C and S2A ). There was up to a 14.2-fold reduction in the release of infectious virions from TRAF6-deficient cells compared with cells expressing TRAF6 ( Figure 2B ). Moreover, NS3 and E proteins were readily detectable in LGTV-infected WT MEFs compared with TRAF6 À/À MEFs ( Figures 2C and S2A). We observed a similar reduction in LGTV replication when we infected CRISPR/Cas9-generated TRAF6 À/À HEK293 cells ( Figure S2B ). To demonstrate that the reduction in LGTV titers was due to a lack of TRAF6, we complemented TRAF6 À/À HEK293 cells with human TRAF6-GFP and found that LGTV titers were restored to WT levels ( Figure 2D ). In addition, we functionally depleted HEK293 cells of TRAF6 using a commercially available TRAF6 peptide inhibitor (Hou et al., 2014) and by overexpressing a TRAF6 construct with a mutation in the ligase catalytic site (Ning et al., 2008) . In both cases, LGTV replication was significantly diminished to levels similar to TRAF6 À/À cells ( Figures S2C-S2E ). Conversely, LGTV replication was similar between TRAF6-GFP overexpressing cells and control cells, suggesting that endogenous TRAF6 is sufficient for the observed proviral effect during LGTV infection ( Figures 2D, S2D , and S2E). Furthermore, we infected TRAF6 À/À cells with the highly virulent TBEV and KFDV and observed similar trends as with LGTV ( Figures 2E, 2F , S2F, and S2G). There was a 9.9-fold reduction in TBEV and 8.6-fold reduction in KFDV titers in TRAF6 À/À MEFs at 24 hpi (Figures 2E and 2F) , suggesting that TRAF6 promotes the replication of TBFVs regardless of their virulence.
To assess the interplay between TBFV replication, TRAF6, and IFN production, we quantified IFN-b in the supernatant of LGTV-infected TRAF6 À/À MEFs. We were only able to detect IFN-b (20.6 pg/mL) at 72 hpi in the supernatant from WT MEFs. IFN-b remained undetectable in the supernatants from TRAF6 À/À MEFs throughout the course of infection ( Figure 2B ). Moreover, the levels of IFN-b directly correlated with the expression of the IFN-stimulated genes, IFIT2 and IFIT3, as detected by immunoblot of the cell lysates (Figure 2C) . These data indicate that the attenuation of LGTV replication in TRAF6 À/À MEFs is not due to increased IFN production.
To compare the impact of TRAF6 on TBFVs to MBFVs, we infected TRAF6 À/À MEFs with WNV and KUNV.
We observed a striking difference between the MBFVs and TBFVs ( Figures 2G-2J ). The replication of WNV and KUNV was enhanced in the absence of TRAF6, both reaching higher viral titers in MEFs deficient in TRAF6 compared with WT ( Figures 2G and 2I ). Infection of TRAF6 À/À MEFs resulted in up to 8.9-fold increase in KUNV titers and an increase in NS3 production compared with WT MEFs ( Figures 2H-2J ). Taken together, these results show that TRAF6 specifically supports TBFV replication, which is distinctly different from its antiviral role in MBFV infection.
Mutation of TBM2 Prevents TRAF6-NS3pro Interaction and Reduces Accumulation of the Mature Protease
Previous studies have shown that mutation of the anchor glutamic acid residue in a TBM to an alanine disrupts TRAF6 binding (Verstak et al., 2014; Yu et al., 2016) . To determine which TBM(s) in LGTV NS3pro interacts with TRAF6, we mutated the acidic amino acid in each TBM of LGTV NS2B/3pro to alanine. We tested the ability of each mutant to bind TRAF6 by coAP assay. We found that a D19A mutation in TBM1 had no effect on binding, whereas an E117A mutation in TBM2 resulted in a significant decrease in binding to TRAF6 ( Figure 3A ). E117A mutation also diminished the TRAF6 interaction to NS2B/3pro_D19A mutant ( Figure 3A ). Quantification of immunoblots using densitometry showed a 56.1% and a 58.6% decrease in pull down of TRAF6 by LGTV NS2B/3pro_E117A and LGTV NS2B/3pro_D19A_E117A, respectively ( Figure 3B ).
After performing coAP assays with LGTV NS2B/3pro mutants, we noticed that constructs with an E117A mutation had reduced levels of the cleaved, mature form of NS2B/3pro ( Figure 3A ). The disappearance of NS3pro could be due to a structural change in protein stability, or a functional change in protease activity leading to decreased autoproteolytic cleavage. To confirm that the lower-molecular-weight protein was produced by autocatalytic cleavage, we inactivated the protease by an additional S138A mutation, which resulted in a total loss of the lower molecular weight band ( Figure 3C ). Quantification of immunoblots by densitometry showed that the E117A mutation reduced mature NS3pro accumulation by 82.5% compared with the WT or D19A proteins ( Figure 3D ).
To further assess the TRAF6-NS3pro interaction at TBM2, we modeled the interaction of LGTV NS3pro and TRAF6 in silico. The crystal structures of TRAF6 and substrate ligands have been solved for several complexes and demonstrate a specific pattern of hydrogen bonding between the MATH domain of TRAF6 and the TBM of an interacting protein Ye et al., 2002) . Indeed, it was from these structures and through mutational analysis that the canonical TBM was determined. We set out to use these data to evaluate the structural interaction of LGTV NS3pro and TRAF6 through TBM2. Unfortunately, no crystal structure exists for any TBFV NS3. So, we began by first generating an LGTV NS3pro model using homology modeling with Murray Valley encephalitis virus NS3 crystal structure as a template ) ( Figure S3A ). TBM2 of LGTV NS3pro was found to form a beta strand that is situated on the surface of the protein ( Figure S3B ). Next, we modeled the structure of the complex of the TBM2 of LGTV NS3pro with the MATH domain of TRAF6 ( Figure 3E ). The negatively charged omega oxygen atom of E117 of LGTV NS3 formed dual hydrogen bonds with the backbone amide N-H groups of L457 and A458 of TRAF6 ( Figure 3E ). The intermolecular interaction energies between E117 of LGTV NS3pro and their interacting protein partners in TRAF6 were calculated at the MP2/6-311++G** level using the supermolecular approach with the Gaussian 09 package ) as described previously . The resulting interaction energies in both the gas phase (DE gas ) and the solution phase (DE solution ) are listed in Table 1 . For comparison, the calculated intermolecular interaction energies between the mutated A117 residue of LGTV NS3 and their interacting protein partners are also listed. In the NS3pro_E117A mutant, the dual hydrogen bonds are lost, which results in a binding energy loss of 3.44 kcal/mol in the solution phase. Overall, both in silico and biological data support the conclusion that an E117A mutation in NS3pro interferes with TRAF6 binding. The unexpected result of the E117A mutation on the abundance of mature NS3pro warrants further studies into the potential effect(s) of TRAF6 on NS3pro structure and protease function.
An LGTV Mutant Virus Containing the E117A Mutation Exhibits a Small Plaque Phenotype and Is Attenuated In Vitro
To test the impact of an E117A mutation on the ability of LGTV to replicate, we created the mutation in the LGTV infectious clone. The plaque-forming ability of the LGTV NS3_E117A mutant was noticeably reduced compared with that of the LGTV following transfection of equal amounts of in vitro transcribed mRNA (Figure 4A) . Also, recovered LGTV NS3_E117A foci were reduced by 81.8% compared with recovered WT and NS3_D19A LGTV ( Figure 4B ). Consistently, we observed reduced replication of LGTV NS3_E117A in HEK293 cells compared with LGTV and LGTV NS3_D19A by immunofluorescent microscopy, immunofocus assay, and immunoblotting ( Figures 4C-4E ). There was up to a 17.4-fold reduction in the release of infectious virions from LGTV NS3_E117A-infected cells compared with cells infected with LGTV or LGTV NS3_D19A ( Figure 3D ). To test if LGTV NS3_E117A attenuation is due to an impaired ability to co-opt TRAF6 during replication, we infected WT and TRAF6 À/À MEFs with LGTV NS3_E117A and LGTV. Similar to observations made with HEK293 cells, replication of LGTV NS3_E117A was reduced by 7.8-fold compared with LGTV in WT MEFs ( Figure 4F ). Alternatively, the attenuation of LGTV NS3_E117A was lost in TRAF6 À/À MEFs; there was no statistical difference between titers from LGTV NS3_E117A and
LGTV-infected TRAF6 À/À MEFs ( Figure 4F ). Taken together, these data suggest that an E117A mutation in NS3 impairs LGTV replication and that this attenuation is dependent on TRAF6.
DISCUSSION
In this study, we provide evidence that TRAF6 plays an unexpected proviral role in TBFV replication. We found that TRAF6 interacts with TBFV NS3pro in a sequence-dependent manner and that targeted inhibition of the complex formation leads to virus attenuation.
We have identified a non-canonical TBM that appears to be conserved among closely related TBFVs and is not present in MBFVs ( Figure 1A) . A physical interaction between flavivirus NS3 and TRAF6 has not been previously reported. It has been shown that NS3 from classical swine fever virus (CSFV), a pestivirus, binds Figure S3 . and degrades TRAF6 to prevent activation of NF-kB signaling pathways during infection (Lv et al., 2017) . Although CSFV is a member of the Flaviviridae, it differs from flaviviruses in several ways.
(1) The genome of CSFV is composed of a different number and set of genes than flaviviruses (Tautz et al., 2015) ; (2) CSFV NS3 requires NS4A, not NS2B, as an essential cofactor of protease activity (Tautz et al., 2000) ; (3) CSFV is not transmitted by arthropod vectors; and (4) CSFV does not cause disease in humans (Blome et al., 2017) .
TRAF6 is conventionally associated with host innate immune protection because of its pivotal role in IL-1/TLR and RIG-I signaling (Inoue et al., 2007; Yoshida et al., 2008) . It was previously shown that prototypical RNA viruses replicate better and are more cytopathic in TRAF6-deficient cells because of a mitigated IFN response (Konno et al., 2009; Yoshida et al., 2008) . Studies examining the role of TRAF6 during flavivirus infection have been limited to MBFVs. DENV and Japanese encephalitis virus (JEV) have been found to up-regulate cellular miR-146a to decrease expression and signaling of TRAF6; suppression of TRAF6 leads to decreased NF-kB activation, Jak-STAT signaling, and IFN production, and in the case of DENV, also inhibited virus-induced autophagy (Pu et al., 2017; Sharma and Verma, 2015; Wu et al., 2013) . The effect of TBFV NS3 binding to TRAF6 is an intriguing and unexplored question for follow-up studies, especially if TBFV NS3 binding to TRAF6 inhibits the canonical antiviral signaling role for TRAF6, while using TRAF6 to benefit virus replication.
It was unexpected when we observed better replication of TBFVs in WT MEFs compared with TRAF6
À/À MEFs (Figures 2A-2C , 2E, and 2F). Indeed, because our findings differ from precedent, we took multiple approaches to validate the proviral effects of TRAF6 in TBFV infection.
(1) We used two independently generated TRAF6 knockout cell lines: embryonically derived TRAF6 À/À MEFs and CRISPR/Cas9 generated TRAF6 À/À HEK293 cells (Figures 2A-2C and S2B). (2) We functionally depleted WT cells of TRAF6 by overexpressing an enzymatically inactive TRAF6 mutant ( Figures S2D and S2E) . (3) We treated WT cells with a TRAF6 inhibitor peptide ( Figure S2C ). (4) We mutated TBM2 within a TBFV genome (Figure 4 ). Under all these conditions, we consistently saw TBFV attenuation. Furthermore, the phenotype could be rescued by the expression of TRAF6 ( Figure 2D ).
When we assessed MBFV replication in our TRAF6 À/À MEFs, using WNV and KUNV, we observed a reciprocal phenotype than what was seen with TBFVs. MBFV replication was enhanced in the absence of TRAF6, similar to previous DENV and JEV studies ( Figures 2G-2J ). As predicted from our sequence analysis (Figure 1A) , KUNV NS3 did not interact with TRAF6 during infection ( Figure 1D ). Furthermore, we saw better LGTV replication in WT MEFs compared with TRAF6 À/À MEFs despite higher IFN-b production ( Figure 2B ).
Taken all together, our findings demonstrate that the proviral function of TRAF6 is specific to TBFVs.
An E117A mutation in TBM2 of NS3pro revealed that interaction with TRAF6 is needed for the accumulation of the mature processed form of the protease. Note that TRAF6-NS3pro binding is not essential for protein function. This allowed us to design and recover mutant LGTV NS3_E117A, which was attenuated to similar levels seen with WT LGTV in TRAF6-deficient cells ( Figures 4D and S2B) . We failed to precipitate TRAF6 from LGTV NS3_E117A-infected cells (data not shown); these experiments were confounded by reduced viral protein levels associated with the LGTV NS3_E117A ( Figure 4E ). LGTV NS3_E117A attenuation is most likely a result of decreased interaction with TRAF6 because the difference between mutant and WT virus is lost in TRAF6 À/À MEFs ( Figure 4F ). In contrast, overexpression of TRAF6 did not enhance virus production, suggesting that the endogenous level of TRAF6 is sufficient for optimal virus replication ( Figures  2D and S2D) , albeit viral protein levels were modestly elevated ( Figure S2E ).
We are currently evaluating how TRAF6 benefits TBFV replication, looking specifically for structural changes to NS3pro when complexed with TRAF6 and changes to overall protease activity. TRAF6 is an E3 ubiquitin ligase and performs its normal physiological function by ubiquitinating itself and substrate proteins (Walsh et al., 2015) . TBFV NS3pro may be modified by TRAF6-mediated non-degradative ubiquitination; this hypothesis is supported by our observation of LGTV attenuation in cells overexpressing an enzymatically inactive TRAF6 ( Figures S2D and S2E ). It has previously been shown that K27-linked ubiquitination of DENV NS3 facilitates NS2B recruitment and NS2B/3pro complex formation; the ligase has yet to be identified . The flavivirus NS3 is an attractive therapeutic target because it is essential for virus replication and has well-characterized enzymatic functions (Leyssen et al., 2000) . Substantial effort and resources have been put into the design of inhibitors of NS3pro activity, but there has only been limited success and no compound has reached the clinical trial stage. It has been challenging to develop NS3pro inhibitors because the active site is shallow and highly charged (Luo et al., 2015) . We propose that the TRAF6-NS3pro interaction may serve as an antiviral target. Specific disruption of the TRAF6-NS3pro complex, as demonstrated by our use of a TRAF6 inhibitor peptide in this study ( Figure S2C ), could indirectly inhibit NS3 function and be accomplished without having to overcome the multiple obstacles that are associated with development of compounds that directly inactivate NS3. Likewise, we speculate that the attenuation and small plaque phenotype of the E117A mutant virus in vitro may result in impaired in vivo pathogenesis as reported for other mutant flaviviruses, including LGTV Eastman and Blair, 1985; Hanley et al., 2002; .
Overall, our study demonstrates that specific flavivirus therapeutic targets may be identified by first understanding how viruses and host cell proteins interact. By identifying a specific interaction between TRAF6 and TBFV NS3pro, we revealed a mechanism used by viruses to co-opt host cell antiviral molecules for viral gain.
Limitations of the Study
There are still many issues to be investigated regarding the role of TRAF6 in TBEV infection, including (1) the exact mechanism as to how a TRAF6-NS3pro interaction affects mature NS3pro accumulation and ultimately virus replication; TRAF6, a E3 ubiquitin ligase, may ubiquitinate NS3 directly or act as a scaffold protein bring together other host or viral proteins; and (2) the importance of TRAF6 in TBFV pathogenesis in primary cells, including dendritic cells and neurons, and within in vivo models. (3) Our investigations only examine the proviral role of TRAF6 in TBFV infection; however, TBFV antagonism of the antiviral activity of TRAF6 likely contributes to the overall success of TBFVs to cause disease.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. Figure S1 .
SUPPLEMENTAL INFORMATION
LGTV NS3pro interacts with TRAF6. Related to Figure 1. (A) Sequence identity and similarity of NS3pro, TBM1, and TBM2 of TBFVs compared to TBEV.
(B) Sequence logo of TBM1. [α-GFP] NS2B/3pro_S138A [α-V5] NS2B/3pro_S138A [α-V5] TRAF6 [α-GFP] β-actin [α-β-actin] Input co-AP: TRAF6 Mock NS2B/3 _S138A + TRAF6 NS2/B_S138A TRAF6 NS2B/3_S138A [α-Mch] TRAF6 [α-V5] TRAF6 [α-V5] NS2B/3_S138A [α-Mch] β-actin [α-β-actin] Input (C) Sequence logo of TBM2.
(D-E) Co-AP of LGTV NS2B/3_S138A and LGTV NS2B/3pro_S138A constructs with TRAF6. HEK 293 cells were transfected with 2 μg of each indicated plasmid. Cell lysates were pulled down using streptavidin-conjugated beads at 24 hours post-transfection and eluted proteins were analyzed by immunoblot with indicated antibodies. Results representative of three independent experiments. Figure S2 . TRAF6 is a proviral factor for TBFVs. Related to Figure 2. (A) Immunoblot analysis of whole cell extracts from WT or TRAF6 -/-MEFs infected with LGTV (MOI 0.1) for indicated times (hr). Blots were probed with antibodies to LGTV NS3, LGTV E, IFIT2, IFIT3, TRAF6, and b-actin. Results representative of three or more independent experiments. Long exposures of LGTV NS3 and LGTV E are included in order to assess viral protein levels during infection of TRAF6 -/-MEFs. β-actin [α-β-actin] hpi E [α-E] TRAF6 IFIT-2 IFIT-3 24 48 72 Mock C (B) Titration of infectious particles in the supernatant from WT or TRAF6 -/-HEK 293 cells infected with LGTV (MOI of 0.1) for indicated times (hr). Virus titers were determined by plaque assay. Data are representative of three or more independent experiments performed in triplicate and plotted as mean +/-SEM. ns, not significant; **p<0.01; ****p<0.0001.
(C) Titration of infectious particles in the supernatant from HEK 293 cells pretreated with 150 µM TRAF6 inhibitor peptide or control peptide for 6 hr prior to infection with LGTV (MOI 1). Supernatants were collected at 48 hpi and titrated by immunofocus assay. Data are presented as percent replication relative to control peptide-treated cells. Data are representative of two independent experiments performed in triplicate and plotted as the mean +/-SEM. *p<0.05.
(D) Titration of infectious particles in the supernatant from HEK 293 cells stably expressing GFP, TRAF6-GFP, or TRAF6-C70A-GFP infected with LGTV (MOI of 10) for indicated times (hr). Virus titers were determined by immunofocus assay. Data are representative of three independent experiments performed in triplicate and plotted as mean +/-SEM. ns, not significant; *p<0.05; **p<0.01.
(E) Immunoblot analysis of whole cell extracts from the infected cells in (C) (48 and 72 hpi). Blots were probed with antibodies to LGTV NS5, LGTV NS1, GFP, and b-actin. Results representative of three independent experiments.
(F-G) Titration of infectious particles in the supernatant from WT or TRAF6 -/-HEK 293 cells infected with TBEV (F) or KFDV (G) (MOI of 0.1) for indicated times (hr). Virus titers were determined by plaque assay. Data are average of three independent experiments performed in triplicate and plotted as mean +/-SEM. ns, not significant; ***p<0.001. LGTV AAF75259 19 DVKNGVYRIYTPGLLWGQRQIGVGYGAKGVLHTMWHVTRGAALLVDGVAVGPYWADVREDVVCYGGAWSLESRWRG-ETVQVHAFPPGRA 107 MVEV CAA27184 71 DTTPGVYRIMARGILG-RYQAGVGVMHEGVFHTLWHTTRGAAIMSGEGRLTPYWGNVKEDRVTYGGPWKLDQKWNGVDDVQMIVVEPGKP 159 * ***** . *.* . * *** ** **.** *****.. . *** *.** *.*** * *. .* * . **. **.
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LGTV AAF75259 376 AIARALRQRGKSVICLNSKTFDKEYSRVKDEKPDFVVTTDISEMGANLDVTRVIDGRTNIKP---EEVDGRIELTGTRRVTTASAAQRRG 462 MVEV CAA27184 425 EIAQCLQRAGKRVIQLNRKSYDTEYPKCKNGDWDFVITTDISEMGANFGASRVIDCRKSVKPTILDEGEGRVILSVPSAITSASAAQRRG 514 **..*.. ** ** ** *..* ** . * ***.********** .**** * .** .* .**. *. .*.********
LGTV AAF75259 463 RVGRQGGRT-DEYIYSGQCDDDDSGLVQWKEAQILLDNITTARGPVATFYGPEQERMTETAGHYRLPEEKRKHFRHLLAQCDFTPWLAWH 550 MVEV CAA27184 515 RVGRNPSQIGDEYHYGGGTSEDDTMLAHWTEAKILLDNIHLPNGLVAQLYGPERDKTYTMDGEYRLRGEERKTFLELIKTADLPVWLAYK 604 ****. . *** * * . .**. * .* **.****** * ** ****... * *** * ** * *. .* *** .
LGTV AAF75259 Isolation, culture, and immortalization of MEFs. Fifteen-day old C57BL/6 +/-mouse embryos were collected, washed with PBS, and torsos were removed. Torsos were washed with PBS, minced, placed in 0.05 % trypsin-EDTA (Invitrogen) containing 1 µg/ml DNase I (Ambion) and incubated at 37°C for 15 min. Cells were filtered using a 100 µM nylon strainer, centrifuged (500 x g, 5 min), resuspended in complete DMEM, and plated in tissue culture flasks (passage 1). Embryo genotypes were determined by TRAF6-specific PCR and only homozygote TRAF6 +/+ and TRAF6 -/-cells were used in subsequent experiments. Cells were immortalized by knockdown of p53 using commerciallyavailable lentivirus preparations (sc-29436-V, Santa Cruz Biotechnology). All animal experiments were done in compliance with the guidelines of the Animal Care and Use Committee of the NIH.
Generation of HEK 293 TRAF6 knock-out cells. WT HEK 293 cells (1 x 10 6 cells/well of a 6-well plate) were transfected with 2 µg of commercially available TRAF6 CRISPR/Cas9 knock-out plasmids (sc-400117, Santa Cruz Biotechnology) or Control CRISPR/Cas9 plasmid (sc-418922, Santa Cruz Biotechnology) using Lipofectamine 3000 Reagent (100022052, Invitrogen). The TRAF6 CRISPR/Cas9 knock-out plasmids consists of a pool of 3 plasmids, each encoding the Cas9 nuclease, a TRAF6-specific 20 nt guide RNA, and GFP marker. The Control CRISPR/Cas9 plasmid contains a non-targeting 20 nt scramble guide RNA and GFP marker. At 24 hours post-transfection (hpt) GFP was visualized to assess transfection efficiency, which was greater than 95%. Transfected cells were then isolated by serial dilution and plated in a 48-well plate. Individual wells were inspected by microscopy 4 days post-transfection to confirm the presence of a single clone and then allowed to continue to grow until reaching roughly 75% confluency. Cells were then trypsinized, equally divided, and plated in 2 wells of a 6-well plate. When cells reached 75% confluency, whole cell extract of each duplicate well was immunoblotted to confirm the absence of TRAF6 using a-TRAF6 (roughly 10% of clones did not express TRAF6). A single isolate was propagated and used for all subsequent studies. Furthermore, the isolate was confirmed to have loss GFP expression (because lack of selection) by microscopy and immunoblot.
Antibodies. The following antibodies were used: a-b-actin (AM4302, Ambion); a-GFP (632381, Clontech and ab32146, Abcam); a-DsRed (632496, Clontech); a-V5 (46-0705, Invitrogen); a-HA (16B12, Covance); a-TRAF6 (ab33915, Abcam); a-TBEV (VR79; ATCC); affinity purified chicken a-LGTV NS3 and control IgY antisera (custom prepared by Aves Labs and a-LGTV NS3 (provided by Dr. S. Best, NIAID, NIH, ); a-LGTV E and a-LGTV NS1 (provided by Dr. C. Schmaljohn, USAMRIID); a-WNV NS3 (R&D Systems, MAB2907); a-IFIT2 and a-IFIT3 (provided by Dr. S. Chattopadhyay, University of Toledo (Chattopadhyay et al., 2016) ). Immunofocus assay. Cells were infected with LGTV at indicated MOI and viral supernatants collected at various time points post-infection. All samples were stored at -80°C until time of titration. 24 hr prior to set up, 24-well plates were seeded with 2 x 10 5 Vero cells per well. 250 μL of 10-fold dilutions of viral supernatants (ranging from 10 0 to 10 -8 , depending on MOI) were added to individual wells. After a 1 hr adsorption period, the inoculum was removed, and the cells were overlaid with DMEM containing 0.8% methylcellulose (w/v) and 2% (vol/vol) FBS. At 5 days post-adsorption, wells were washed twice with DPBS and fixed with 100% methanol for 20 min at room temperature (RT). Plates were washed twice with DPBS and blocked with Opti-MEM (31985-070, Thermo Fisher Scientific) for 30 min at RT. Blocking Opti-MEM was removed and a-LGTV E (1:1000) and a-LGTV NS1 (1:1000) in Opti-MEM added to each well. Plates were incubated for 1 hr at 37°C, washed twice with DPBS, and then incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (1:1000, A28177, Thermo Fisher Scientific) in Opti-MEM for 1 hr at 37˚C. Plates were washed twice with PBS and FFUs were visualized by adding freshly prepared peroxidase solution containing 0.4 mg/ml 3,3'-diaminobenzidine (D5637, Sigma) and 0.0135% hydrogen peroxide in DPBS.
Plaque assay. Cells were infected with KUNV, WNV, KFDV, or TBEV at indicated MOI and viral supernatants collected a various time points post-infection. All samples were stored at -80°C until time of titration. 24 hr prior to set-up, 24-well plates were seeded with 2 x 10 5 Vero cells per well. 250 μL of 10-fold dilutions of viral supernatants (ranging from 10 0 to 10 -10 , depending on MOI) were added to individual wells. After a 1 hr adsorption period, the inoculum was removed, and the cells were overlaid with Minimum Essential Medium (MEM, 10370-021, Thermo Fisher Scientific) containing 1.5% carboxymethylcellulose (w/v, C4888, Sigma). At 4 days post-adsorption, cells were fixed with 10% formaldehyde for 1 hr at RT and then washed with water to remove all residual overlay media. To visualize plaques, crystal violet solution (1% crystal violet in 25% ethanol) was added to each well and incubated for 15 min at RT and then washed extensively to remove residual crystal violet.
Immunofluorescence confocal microscopy. Cells were plated in 8-well Lab-Tek II chamber slides (154534, Thermo Fisher Scientific) and prepared by washing twice with DPBS before fixing with fresh 4% paraformaldehyde (43368, Alfa Aesar) for 20 min at RT. Cells were washed 3 times with DPBS-T (PBS, 0.5% Tween-20) and then incubated with permeabilization buffer (0.1% Triton X-100, 0.1% sodium citrate) for 5 min at RT. Slides were blocked in DPBS, 0.5% BSA, 1% goat serum for 1 hr at RT. Cells were then incubated with primary antibody for 1 hr at RT, washed 3 times with DPBS-T and incubated with appropriate secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 594 (A11029, A11042, Thermo Fisher Scientific) for 1 hr at RT. Slides with GFP were stained with anti-GFP conjugated to Alexa Fluor 488 (A21311, Thermo Fisher Scientific). Slides were washed 3 times with DPBS-T in the dark and overlaid with glass coverslips using Prolong Gold Antifade Reagent with DAPI (P36931, Thermo Fisher Scientific). Stained cells were visualized using an Olympus confocal microscope (Olympus Fluoview FV1000).
Immunoblotting. Cells were washed twice in DPBS and harvested in 1 mL radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1 % SDS, 1% NP-40, 0.5% Na-deoxycholate) with Pierce Protease Inhibitor Tablets, EDTA Free (PI, 88266, Thermo Fisher Scientific). To ensure complete lysis, samples were subjected to three snap freeze/thaw cycles in liquid nitrogen. Samples were treated with 10 units of Turbo DNAse (AM2238, Thermo Fisher Scientific) and insoluble cellular debris was removed by centrifugation (10000 x g for 10 min at 4°C). Protein concentration of samples was determined by DC Protein Assay (5000111, Bio-Rad). Equal amounts (10-Resource for Functional Sites in Proteins (http://elm.eu.org, ). Sequence alignments and calculations of sequence percent identity/similarity were made using MacVector version 12.7.0. Sequence logos of TBMs were generated with WebLogo version 2.8.2 (http://weblogo.berkeley.edu/logo.cgi, (Crooks et al., 2004) ).
Molecular modeling of the TRAF6-NS3pro binding. A 3D structural model for the TRAF6-NS3pro complex was generated using a two-stage protocol. For the first stage, the three-dimensional structure for NS3pro from LGTV was predicted by means of homology modeling using the SWISS-MODEL Workplace (Arnold et al., 2006) because no crystal structure exists for any TBFV NS3pro. Murray Valley encephalitis virus (MVEV) NS3pro was used as a template for modeling because it was found to have the highest sequence identity (46%) among solved MBFV NS3pro crystal structures ( Figure S3A ). This high sequence homology lays the foundation for the generation of a reliable homology model for LGTV NS3pro based on the 2.75 Å resolution x-ray crystal structure of NS3pro from MVEV (PDB: 2WV9, ). Figure S3B displays the modeled structure of the LGTV NS3pro.
During the second stage, TBM2 of the model LGTV NS3pro structure was docked with the C-terminal MATH domain of TRAF6 from Homo sapiens by means of quantum mechanics/molecular mechanics (QM/MM) optimization to form the TRAF6-LGTV NS3pro complex. Initially, TBM2 of the model LGTV NS3pro structure was placed into the binding site of TRAF6 utilizing the crystal structure of a previously reported TRAF6-MAVS complex (PDB: 4Z8M, ) as a template. The QM layer contained TBM2 and its directly interacting protein residues of TRAF6 and was treated at the PM3 level. The MM layer included the rest of the TRAF6 protein and was described by the AMBER force field. The QM/MM optimization was performed using the Gaussian 09 package . The QM/MM two-layer partitioning was carried out as previously described (Liu and Hu, 2006) . The modeled structure of the complex of the TBM2 motif of LGTV NS3pro with the C-terminal MATH domain of TRAF6 is shown in Figure 3E .
The intermolecular interaction energies between E117 of LGTV NS3pro and its interacting protein partners in TRAF6 were calculated at the MP2/6-311++G** level using the supermolecular approach as previously described . In the supermolecular approach, the intermolecular interaction energy between the two monomeric molecules (e.g. A and B) is computed as the difference between the energy of the interacting dimer EAB and the energies of the monomers EA and EB: DEint = EAB -EA -EB. The basis set superposition error (BSSE) was corrected by the Boys and Bernardi Counter Poise Method (Boys and Bernardi, 1970) . All calculations were carried out using the Gaussian09 software . For the gas phase interaction energy DE gas , the electronic energies for all molecular species (Ei, i=AB, A, B) are calculated directly. For
